Description: September 2015 Reinsurance News

Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments

Description: Over the years I have come to believe that the nature vs nurture debate is fundamentally flawed, in that it tends to exclude an increasingly important third influence: culture.

Description: In 2014, the SOA Product Development and Reinsurance Sections, along with the Committee for Life Insurance research engaged Reinsurance Group of America to undertake a research project on term conversion experience.

Description: This session provides an overview of industry approaches to valuing the liabilities of nontraditional health products. Liabilities for losses that have been incurred but not reported and for losses that have been reported but not paid are examined. Includes a discussion on employer specific stop-loss, provider excess loss, critical illness and cancer insurance. From the Record of the Society of Actuaries, Volume 28, No. 2, Session 133

Description: Specific and aggregate stop loss insurance reinsurance is a product that has unique characteristics. The product is a special type of policy that covers employers or their self-funded employee benefit plans for larger health claims. The product has some unique reserving challenges for the health/reinsurance actuary.

Description: November 2015 Reinsurance News